Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast

NEW YORK and SAN DIEGO, Nov. 20, 2014 /CNW/ -- Cytori Therapeutics (NASDAQ: CYTX), today announced that President and CEO Marc Hedrick, M.D. will present live at VirtualInvestorConferences.com on December 4, 2014.

DATE:   Thursday, December 4, 2014
TIME:    11:15 am PT / 2:15 pm ET
LINK:     Click here or paste this URL into your browser's address bar: http://bit.ly/1B2KGaL

It is recommended that investors pre-register to save time and receive event updates.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

"In the past few months, we have substantially focused operations and reprioritized Cytori's key value drivers. Our top corporate goals are to grow the clinical pipeline in the United States, further expand our government and corporate partnering efforts and bring our commercial activities to positive cash flow," said Dr. Hedrick. "We invite our investors and supporters to connect and learn more about these recent changes. Also, we will provide an update on the new regenerative medicine law in Japan and what it means for Cytori, and discuss our plan for rebuilding value in Cytori for our shareholders and for the patients who can benefit from Cytori Cell Therapy."

Recent Company Highlights

• BARDA, a branch of the U.S. government, executed a contract extension option with Cytori to significantly expand funded research and development activities for a medical countermeasure to be used in the treatment of thermal burns and radiation injury.
• Cytori will complete six-month patient follow-up from the U.S. ATHENA trial for heart failure due to ischemic heart disease and expects to complete this analysis in 1Q2015.
• Received FDA approval to begin a U.S. IDE trial of Cytori Cell Therapy on patients with knee osteoarthritis with enrollment scheduled to begin in early in 2015.
• Completed enrollment and preliminary analysis of a 20-patient E.U. feasibility study for use of Cytori Cell Therapy in the treatment of patients with anterior cruciate ligament (ACL) injuries.
• Reported publication in the Annals of the Rheumatic Diseases of the results of six-month outcomes in a 12-patient feasibility study of the use of Cytori Cell Therapy in patients with scleroderma-associated hand disease.

About Cytori Therapeutics
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat a variety of medical conditions. Multiple scientific publications suggest that Cytori Cell Therapy and ADRCs improve blood flow, moderate the inflammatory response and facilitate wound repair. As a result, we believe these cells can be applied with success across multiple disease states. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. For more information: visit www.cytori.com or follow on Twitter www.twitter.com/cytori.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts, including statements regarding our ability to provide updated timelines for completion of enrollment of the osteoarthritis clinical trial, our ability to obtain expanded contract options with BARDA, our ability to complete data review associated with six-month patient follow-up from the U.S. ATHENA trial, those regarding our belief in the safety and feasibility in using Cytori Cell Therapy for treatment of scleroderma-associated hand disease and treatment of anterior cruciate ligament (ACL) tears and therapeutic potential to accelerate healing and recovery with Cytori Cell Therapy for the treatment of such conditions, our expectation of continuing demand from investigator initiated trial customers, are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, the quality of data supporting execution of BARDA contract options, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including in its most recent annual and quarterly reports.

There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.

SOURCE Cytori Therapeutics